NCT07018388Enrolling by invitation
Intrapatient Comparison of STN and GPi tTIS in PD
Intrapatient Comparison of Subthalamic and Globus Pallidus Internus Temporal Interference Stimulation in Parkinson's Disease
Source: ClinicalTrials.gov · Last updated 22 Apr 2026
Brief summary (registry, in English)
The goal of this clinical trial is to investigate the therapeutic efficacy of tTIS in patients with Parkinson's disease and to evaluate the immediate effects and conduct intrapatient comparisons of individualized 130 Hz Subthalamic Nucleus-transcranial Temporal Interference Stimulation (STN-tTIS) and Globus Pallidus Internus-transcranial Temporal Interference Stimulation (GPi-tTIS) on motor symptoms in patients with early to mid-stage Parkinson's Disease (PD) during "off" medication states. The main questions this study aims to answer are: 1. Can tTIS significantly improve the motor symptoms of patients with Parkinson's disease? 2. Is the therapeutic effect of STN-tTIS superior to that of GPi-tTIS?
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 5 Jun 2025
- Start date
- 23 Apr 2025
- Primary completion date
- 1 Nov 2026
- Lead sponsor
- Ruijin Hospital
- Diseases
- Parkinson disease
- NCT number
- NCT07018388
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 23 Apr 2025 to the primary completion date, 1 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Antipsychotics, antidepressants, or dopamine modulators outside of PD drugs;
Other illness
- Presence of neurological disorders that may affect the study (e.g., traumatic brain injury);
- Metal devices in the head or heart (e.g., deep brain stimulators, pacemakers);
Other
- Unstable vital signs.
Who the study is looking for
- Diagnosis of primary Parkinson's disease (MDS);
- Hoehn \& Yahr stage ≤ 3;
- Antiparkinsonian drugs must have remained unchanged in the past four weeks, and the dosage must have remained stable throughout the study.
Age in the registry: 50 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ruijin hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.